[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535839":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":21,"locations":30,"responsibleParty":48,"collaborators":7,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":7,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Xijing Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"PROCEDURE","Transcatheter aortic valve replacement","A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years",[14],"Transcatheter aortic valve implantation",[16,19],{"name":17,"affiliation":5,"role":18},"Ling Tao, M.D, Ph.D","STUDY_CHAIR",{"name":20,"affiliation":5,"role":18},"Rutao Wang, M.D, Ph.D",[22,26],{"name":20,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","+86-15091095796","rutaowang@qq.com",{"name":27,"role":23,"phone":28,"phoneExt":7,"email":29},"Ruining Zhang, BSc","+86-15802990370","ruining-zhang@qq.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ling Tao","RECRUITING","Xi'an","Shaanxi","710032","China","CN",{"type":40,"coordinates":41},"Point",[42,43],108.92861,34.25833,{"lat":43,"lon":42},[46],{"name":47,"role":23,"phone":24,"phoneExt":7,"email":25},"Rutao Wang, M.D., Ph.D.",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","LingTao","Professor in Cardiology, Director of the department of Cardiology","100535839","safety-and-efficacy-of-post-marketing-transcatheter-aortic-valves-in-real-world-chinese-patients-100535839",false,"NCT06257043","Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in \"Real World\" Chinese Patients","RECORD TAVR REGISTRY: Prospective, Multi-Center Registry of \"Real World\" Chinese Patients Undergoing Transcatheter Aortic Valve Replacement","Inclusion Criteria:\n\n1. Patients with aortic valve disease are evaluated by the cardiac team and indicate TAVR therapy\n2. Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with aortic valve disease who have been evaluated by a cardiac team as unsuitable for TAVR\n2. Patients who cannot tolerate the materials or medications associated with this study\n3. Women who are pregnant or breastfeeding\n4. Patients who participated in a clinical trial of another drug or medical device before enrollment","ALL","18 Years",{"count":62,"type":63},3000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this prospective multi-center, observational registry in China is to collect clinical baseline, procedural, and follow-up data of all patients treated with TAVR in China and to evaluate short-, mid-, and long-term clinical outcome data of all post-marketing transcatheter valves. Each center will collect baseline and procedural data as well as clinical outcomes for up to 10 years.",[68],"Aortic Valve Disease Mixed",[70,71,72],"Aortic Valve Disease","Real world","TAVR","2024-04-18",{"date":75,"type":76},"2024-04-19","ACTUAL",{"date":78,"type":76},"2023-10-30",{"date":80,"type":63},"2034-01-01",{"name":5,"class":6},1]